8-K/A: ABVC BioPharma Amends 8-K Filing Regarding Non-Reliance on Prior Financial Statements

ABVC BioPharma clarifies its stance on previously issued financial statements, stating that an amendment to the 2023 Annual Report is no longer required due to corrections made in the 2024 Form 10-K.

Summary

• ABVC BioPharma initially reported on April 15, 2024, that its financial statements for the fiscal year ended December 31, 2023, should no longer be relied upon due to errors.
• The company intended to file an amendment to the Annual Report on Form 10-K for the year ended December 31, 2023.
• The errors and misstatements were corrected and audited by Simon & Edward LLP (S&E).
• The audited financial statements as of and for the years ended December 31, 2024 and 2023 were included in the Annual Report on Form 10-K for the year ended December 31, 2024, which was filed on April 15, 2025.
• After discussing the issue with S&E, the company's management determined that the 2023 Amendment is not required, as the corrections were adequately addressed in the Form 10-K.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company addressed the errors, the initial non-reliance notice is a concern. The fact that they corrected the issue in the 10K is positive.

Positives

• The errors in the 2023 financial statements have been identified, corrected, and audited.
• The corrected financial statements have been included in the 2024 Form 10-K, providing stakeholders with accurate information.
• The company is avoiding the additional cost and effort of filing an amendment to the 2023 Annual Report.

Negatives

• The initial need to restate financial statements indicates potential weaknesses in internal controls or accounting practices.

Risks

• The initial errors in the financial statements could raise concerns among investors and regulators.
• Future errors or misstatements in financial reporting could lead to further non-reliance notices and potential legal or regulatory action.

Future Outlook

The company does not provide specific forward-looking statements in this filing beyond the decision not to file an amendment to the 2023 Annual Report.

Management Comments

• Management determined that the 2023 Amendment is not required, as the corrections were adequately addressed in the Form 10-K.

Industry Context

In the biopharmaceutical industry, accurate and reliable financial reporting is crucial for maintaining investor confidence and regulatory compliance. Restatements or non-reliance notices can negatively impact a company's reputation and stock price.

Comparison to Industry Standards

• Companies like Amgen, Gilead Sciences, and Biogen are expected to maintain high standards of financial reporting.
• Any deviation from these standards, such as a non-reliance notice, can be viewed negatively by investors and analysts.
• The prompt correction and disclosure of errors are essential for mitigating potential damage to the company's reputation.

Stakeholder Impact

• Shareholders will be impacted by the clarification regarding the financial statements.
• The correction of errors aims to provide stakeholders with accurate financial information.

Key Dates

Keywords

financial statements, ABVC BioPharma, non-reliance, amendment, Form 10-K, errors, audited